Mostrar el registro sencillo del ítem

dc.contributor.author
Vottero, Lucía  
dc.contributor.author
Lanari, Claudia Lee Malvina  
dc.contributor.author
Fabris, Victoria Teresa  
dc.date.available
2025-07-01T09:45:05Z  
dc.date.issued
2020  
dc.identifier.citation
Effect of Roscovitine and mifepristone in luminal breast cancer cells; American Association for Cancer Research Virtual Annual Meeting II; San Diego; Estados Unidos; 2020; 5828-5828  
dc.identifier.issn
0008-5472  
dc.identifier.uri
http://hdl.handle.net/11336/264803  
dc.description.abstract
The cyclin dependent kinase (CDK)4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) have been recently approved in combination with endocrine therapy for luminal breast cancer treatment. On the other hand, the use of CDK2 inhibitors, such as Roscovitine, appears as a therapeutic alternative to overcome the acquisition of resistance to Palbociclib. However, there are few clinical trials using CDK2 inhibitors for breast cancer treatment. Most of the reports on the effects of Roscovitine were performed in MCF-7 or MDA-MB-231 cells.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
American Association for Cancer Research  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
BREAST CANCER  
dc.subject
CDK INHIBITORS  
dc.subject
ENDOCRINE THERAPY  
dc.subject
PROGESTERONE RECEPTOR  
dc.subject
ANTIPROGESTINS  
dc.subject.classification
Otras Medicina Básica  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Effect of Roscovitine and mifepristone in luminal breast cancer cells  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.type
info:eu-repo/semantics/conferenceObject  
dc.type
info:ar-repo/semantics/documento de conferencia  
dc.date.updated
2022-11-09T18:33:57Z  
dc.identifier.eissn
1538-7445  
dc.journal.volume
80  
dc.journal.number
Suppl. 16  
dc.journal.pagination
5828-5828  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Philadelphia  
dc.description.fil
Fil: Vottero, Lucía. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina  
dc.description.fil
Fil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina  
dc.description.fil
Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://cancerres.aacrjournals.org/content/80/16_Supplement/5828  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1158/1538-7445.AM2020-5828  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.coverage
Internacional  
dc.type.subtype
Reunión  
dc.description.nombreEvento
American Association for Cancer Research Virtual Annual Meeting II  
dc.date.evento
2020-06-22  
dc.description.ciudadEvento
San Diego  
dc.description.paisEvento
Estados Unidos  
dc.type.publicacion
Journal  
dc.description.institucionOrganizadora
American Association for Cancer Research  
dc.source.revista
Cancer Research  
dc.date.eventoHasta
2020-06-24  
dc.type
Reunión